I support the efforts of the Hepatitis C Action and Advocacy Coalition (HAAC) to increase access to treatments for Hepatitis C. Pharmaceutical companies have a right to a reasonable return on their investments in the research and development of life enhancing products. But I am very concerned if the bundling of products leads to reduced access to appropriate therapy, or if marketing practices make it more difficult for researchers to test combinations of drugs. HAAC has sent my office information on the marketing of REBETRON, and we have forwarded this information to the Federal Trade Commission (FTC) for their consideration. We have also been in contact with the Food and Drug Administration and Schering-Plough Pharmaceuticals. We will remain in contact with all these organizations, and will work for a resolution which allows for maximum access to Hepatitis C treatments by patients and researchers.
Current Presss Releases
2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003
2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996